Related Experiment Video
Updated: Dec 4, 2025

11:32
A Neuroscientific Approach to the Examination of Concussions in Student-Athletes
Published on: December 8, 2014
13.1K
FLAME: A computerized neuropsychological composite for trials in early dementia
Helen Brooker1, Gareth Williams2, Adam Hampshire3
1St Lukes Campus The University of Exeter Medical School Exeter UK.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|October 22, 2020
Summary
The FLAME composite score effectively identifies early Alzheimer's disease (AD) and tracks cognitive decline. This tool enhances clinical trial power for AD research.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Clinical Trials
Background:
- Sensitive neuropsychological tests are crucial for enhancing the statistical power of clinical trials in early Alzheimer's disease (AD).
- Current assessments may lack the sensitivity required to detect subtle cognitive changes in the early stages of AD.
Purpose of the Study:
- To develop and validate a novel neuropsychological composite, FLAME (Factors of Longitudinal Attention, Memory and Executive Function).
- To assess the sensitivity of FLAME to cognitive change in individuals with early Alzheimer's disease (AD).
Main Methods:
- A large cohort of 10,714 participants over 50 from the PROTECT study were assessed using computerized cognitive tests over two years.
- Factorial analysis was employed to identify key cognitive factors, followed by sensitivity analyses in participants with stage 2/3 early AD.
Main Results:
- The FLAME composite score, encompassing attention speed and accuracy, memory, and executive function, effectively differentiated normal cognition from early AD at baseline.
- FLAME demonstrated sensitivity to both cognitive and global/functional decline over the two-year study period.
- The composite showed potential for improving statistical power in clinical trials for early AD.
Conclusions:
- FLAME is a sensitive and straightforward computerized neuropsychological composite for assessing change in early Alzheimer's disease.
- This tool offers utility for clinical trials focused on cognitive outcomes in AD, potentially reducing required sample sizes.

